🇺🇸 FDA
Patent

US 11285194

Combination immunotherapy approach for treatment of cancer

granted A61KA61K2039/572A61K31/00

Quick answer

US patent 11285194 (Combination immunotherapy approach for treatment of cancer) held by Calidi Biotherapeutics, Inc. expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Calidi Biotherapeutics, Inc.
Grant date
Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/572, A61K31/00, A61K35/12, A61K35/28